Lucid Diagnostics

Lucid Diagnostics FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Lucid Diagnostics (LUCD) as of Oct 17, 2026 is 80.47 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 98.37 % — a change of -18.19% (lower).

FCF Conversion

80.47 %

YoY

-18.19%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Lucid Diagnostics is 2025 80.47 % . FCF Conversion Rate (FCF/EBITDA) of Lucid Diagnostics was 2024 98.37 % . It decreases by -18.19% lower compared to the previous year.

The Lucid Diagnostics FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
91.70 USD
Jan 1, 2019
53.42 USD
Jan 1, 2020
78.39 USD
Jan 1, 2021
65.99 USD
Jan 1, 2022
54.46 USD
Jan 1, 2023
62.73 USD
Jan 1, 2024
98.37 USD
Jan 1, 2025
80.47 USD
The Lucid Diagnostics FCF Conversion history
YEARFCF ConversionYoY
80.47 %-18.19%
98.37 %+56.81%
62.73 %+15.18%
54.46 %-17.47%
65.99 %-15.82%
78.39 %+46.75%
53.42 %-41.75%
91.70 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lucid Diagnostics Stock analysis

What does Lucid Diagnostics do? Lucid Diagnostics Inc, headquartered in New York City, is a commercial-stage medical diagnostics technology company focused on gastroesophageal reflux disease (GERD) and esophageal cancer prevention. The company, listed on October 14, 2021, employs 82 full-time staff and offers EsoCheck, a noninvasive capsule device for esophageal cell sampling, and EsoGuard, a DNA assay for detecting precancerous conditions. It is developing EsoCure, an ablation device for treating dysplastic Barrett's esophagus to prevent progression to lethal esophageal adenocarcinoma (EAC). Lucid Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lucid Diagnostics stock

FCF Conversion Rate (FCF/EBITDA) of Lucid Diagnostics is 80.47 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Lucid Diagnostics changed from 98.37 % to 80.47 %, representing a -18.19% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Lucid Diagnostics since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Lucid Diagnostics with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Lucid Diagnostics

All Key Metrics — Lucid Diagnostics